Inhalation Sciences AB (publ) releases Q2 Report 2022
(Stockholm, Sweden, 29 August 2022) Inhalation Sciences AB announces that its interim report for the second quarter 2022, January 1 – June 30, is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/Summary of the interim report After processing our FDA application and submitting the requested additional documentation, we have now been granted approval to begin our study. It will be co-funded by the FDA by up to 250,000 USD per year for a 2-year period and will be based on in vitro studies and analysis